Summary
Recombinant activated factor VII (rFVIIa, Novo Seven®) has been successfully used to treat bleeding episodes in patients with antibodies
against coagulation factors VIII and IX. In recent years, rFVIIa has also been employed
for the management of uncontrolled bleeding in a number of congenital and acquired
haemos-
tatic abnormalities. Based on a literature search, this review examines the current
knowledge on therapy with rFVIIa, from the now well-standardized uses to the newer
and less well-characterised clinical applications.
Keywords
Recombinant FVIIa - bleeding - haemophilia - inhibitors